NFKB1 and non-small cell lung carcinoma: Although the NF-κB inhibitor Bay 11–7085 failed to exert the anticipated effect in the present experimental setting (Fig. S3A and B), it is worth noting that this inhibitor has been previously validated to be effective in non-small cell lung cancer [21].